MediNice SA

As of June 30, 2026, MediNice SA carries a market capitalization of 684.43M, placing it among publicly traded companies globally. Its enterprise value stands at 680.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MediNice SA's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, MediNice SA has 9.29M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, MediNice SA maintains a current ratio of 2.31, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is - -, indicating a certain level of leverage, while an interest coverage ratio of -40.62 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, MediNice SA posted a negative return on equity (ROE) of -9.75, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.17, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 10.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, MediNice SA recorded an income tax benefit of -14,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -7.96M and -7.94M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, MediNice SA's stock has gained approximately 317.84% over the past 52 weeks. The 50-day moving average sits at 62.07, while the 200-day moving average is 60.82.

Over the twelve months ended June 30, 2026, MediNice SA generated - - in revenue and converted that into -7.94M in net income, yielding earnings per share of -0.90. EBITDA reached -7.55M, while operating income came in at -7.82M.

As of June 30, 2026, MediNice SA holds 4.18M in cash and equivalents against - - in total debt, resulting in a net debt position of -4.17M. Total book value stands at 84.29M, with working capital of 2.54M providing operational flexibility.

MediNice SA produced -5.91M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.59M in capital expenditures, free cash flow totaled -10.50M - equivalent to -1.19 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.62: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.77, meaning MediNice SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, MediNice SA has an Altman Z-Score of 79.78, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.